CeriBell, Inc. Overview
Pro stress-test →CeriBell is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices, offering a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies. The company's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs. However, the company has evolved to also focus on acute care neurological diagnostics through point-of-care EEG technology.
Strategic Profile
Pro stress-test →CeriBell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions through the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform. The system combines proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms. The company received FDA 510(k) clearance for its Clarity algorithm, becoming the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures, supported by data from over 1,700 patients.
Competitive Landscape
Pro stress-test →CeriBell operates in the small-cap medical device space alongside competitors like Nephros. The point-of-care EEG market is nascent with limited direct competition. The company's AI-powered Clarity algorithm and FDA clearance for seizure detection in pediatric and adult populations (1+ years) represent significant competitive advantages. Indirect competition exists from traditional ICU EEG monitoring and software vendors.
Industry Context
CeriBell, Inc. operates in Medical Devices & Technology - Neurological Diagnostics / Point-of-Care EEG.
Key facts
Founded: 2014 · Headquarters: Sunnyvale, CA, United States · Employees: 281 · Revenue: $85-88M (FY 2025E, 30-34% growth projected) · Market cap: $680.62M - $784.95M